A carregar...
Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis
BACKGROUND: Vandetanib is the most largely used tyrosine kinase inhibitor (TKI) in patients with locally advanced and/or metastatic medullary thyroid cancer (MTC). Here, we conducted a systematic review on its efficacy and attempted to perform a meta-analysis adopting standardized RECIST criteria as...
Na minha lista:
| Publicado no: | Front Endocrinol (Lausanne) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5943569/ https://ncbi.nlm.nih.gov/pubmed/29774010 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2018.00224 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|